adenine and Disease Models, Animal studies

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."	8.85	Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
"Colchicine inhibited tubulin polymerization and caspase-1 activation and attenuated kidney inflammation and fibrosis in a mouse model of adenine-induced KI."	8.31	Beneficiary Effects of Colchicine on Inflammation and Fibrosis in a Mouse Model of Kidney Injury. ( Arazi, E; Landau, D; Segev, Y; Shukri, N; Tobar, A, 2023)
"We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet."	8.12	Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022)
"In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice."	8.12	Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022)
" The characterizations were analyzed by physicochemical methods, and the renoprotections were processed in adenine-induced chronic kidney diseases (CKD) models of mice."	8.02	Renoprotective effects of enzyme-hydrolyzed polysaccharides from Auricularia polytricha on adenine-induced chronic kidney diseases in mice. ( Cui, W; Jia, L; Li, J; Pang, H; Song, X; Zhang, J, 2021)
" Importantly, the neuron-protective effect of MDL-28170 on ischemic insult was reversed by cotreatment with either class III-PI3K (phosphatidylinositol 3-kinase) inhibitor 3-methyladenine or lysosomal inhibitor chloroquine (chloroquine), suggesting that CAPN1 activation-mediated impairment of autophagic flux is crucial for cerebral ischemia-induced neuronal damage."	8.02	CAPN1 (Calpain1)-Mediated Impairment of Autophagic Flux Contributes to Cerebral Ischemia-Induced Neuronal Damage. ( Cai, R; Che, X; Fu, X; Liu, Y; Luo, J; Yang, J; Yang, Y; Yao, Y; Yu, X; Zhang, H; Zhou, MS, 2021)
"The elevated level of the amino acid metabolite homocysteine (Hcy) is known as a risk factor for ischemic stroke."	7.91	Homocysteine enhances neural stem cell autophagy in in vivo and in vitro model of ischemic stroke. ( Cheng, M; Liang, X; Liu, H; Sai, N; Wang, M; Wang, X; Yang, L; Zhang, X, 2019)
"After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects."	7.88	Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018)
"We show that simvastatin treatment mediates activation of autophagy in BSMCs, which is correlated with airway inflammation and airway remodelling in mouse models of asthma."	7.85	Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma. ( Cui, R; Ding, T; Gu, W; Guo, X; Han, F; Li, X; Peng, J; Xu, W, 2017)
"A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)."	7.83	Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016)
" Adenine (5, 10, and 50 mg/kg BW/day) was administered orally for 14 days to female BALB/c mice, and then 5% dextran sodium sulfate (DSS) was given to induce colitis."	7.83	Adenine Inhibits TNF-α Signaling in Intestinal Epithelial Cells and Reduces Mucosal Inflammation in a Dextran Sodium Sulfate-Induced Colitis Mouse Model. ( Fukuda, T; Majumder, K; Matsui, T; Mine, Y; Turner, PV; Zhang, H, 2016)
"This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy."	7.81	Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015)
" Sodium thiosulfate (STS) due to its multiple properties such as antioxidant and calcium chelation has been reported to prevent vascular calcification in uremic rats, without mentioning its impact on cerebral function."	7.81	Sodium thiosulfate protects brain in rat model of adenine induced vascular calcification. ( Kurian, GA; Sriram, R; Subhash, N, 2015)
"In order to evaluate the efficacy, and explore the mechanism of SDG to inhibit the progression of renal fibrosis, study was carried out using the adenine-induced Wister rats as the CRF model, and losartan as postive control drug."	7.80	Chinese herbal medicine Shenqi Detoxification Granule inhibits fibrosis in adenine induced chronic renal failure rats. ( Cai, P; Ma, H; Meng, H; Peng, M; Si, G; Xu, Y; Zhang, X, 2014)
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)."	7.79	Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013)
" The negative impact of inflammation in this CKD model was overcome by the marked anti-inflammatory effects of thalidomide, promoting renal protection."	7.79	Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. ( Blanco, P; Catanozi, S; de Sá Lima, L; Degaspari, S; Dellê, H; Noronha, IL; Santana, AC; Scavone, C; Silva, C; Solez, K, 2013)
"Since homocysteine (Hcy) is considered a risk factor to cerebral diseases and adenine nucleotides are important molecules to brain normal function, in the present study we investigated the effect of chronic mild hyperhomocysteinemia on ectonucleotidase activities and expression in rat cerebral cortex."	7.78	Mild hyperhomocysteinemia alters extracellular adenine metabolism in rat brain. ( Bogo, MR; Bonan, CD; Casali, EA; Ferreira, AG; Savio, LE; Scherer, EB; Schmitz, F; Tasca, RA; Vuaden, FC; Wyse, AT, 2012)
"Adenine phosphoribosyltransferase deficiency in mice or an excessive oral intake of adenine leads to the accumulation of 2,8-dihydroxyadenine (DHA) in renal tubules and that causes progressive renal dysfunction accompanied by interstitial fibrosis."	7.75	Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. ( Aizawa, R; Hori, M; Ozaki, H; Tamura, M, 2009)
"The aim of the present study was to test the hypothesis that inhibition of adenosine deaminase (ADA) enhances the efficiency of signal-transduction of myocardial A1 adenosine receptors in hyperthyroidism."	7.74	Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium. ( Berta, A; Gesztelyi, R; Grenczer, M; Jakab, A; Karsai, D; Kemeny-Beke, A; Pasztor, F; Szentmiklosi, AJ; Vecsernyes, M; Zsuga, J, 2007)
"Oral adefovir dipivoxil (ADV) reduced viral load in transgenic mice expressing hepatitis B virus (HBV)."	7.71	Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. ( Julander, JG; Morrey, JD; Sidwell, RW, 2002)
" In order to further evaluate the role of adenosine in seizure activity, we monitored adenosine and its major biochemical metabolites inosine, xanthine, and hypoxanthine in the dorsal hippocampus by in vivo microdialysis before and during the induction of generalized seizures."	7.70	Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. ( Aden, U; Berman, RF; Fredholm, BB; O'Connor, WT, 2000)
"The inherited disease Lesch-Nyhan syndrome, which is caused by a deficiency of the enzyme hypoxanthine phosphoribosyltransferase (HPRT), is characterized by behavioural alterations, including self-injurious behaviour and mental retardation."	7.68	Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. ( Melton, DW; Wu, CL, 1993)
" Potentially, lower IFN-α and IP-10 levels as well as once-weekly intranasal dosing vs daily subcutaneous or intramuscular dosing with recombinant type I IFNs could explain the lack of pregnancy effects; however, there was an undesired impact on offspring immune function."	5.62	GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys. ( Baker, A; Bray, M; Hillegas, AE; Maier, CC; Phadnis-Moghe, AS; Posobiec, LM; Price, MA; Stanislaus, DJ, 2021)
"Phosphate binders are most used to treat hyperphosphatemia and it is significant to develop its alternatives with high specific and low cost in the clinic."	5.62	Adsorptivity of cationic cellulose nanocrystals for phosphate and its application in hyperphosphatemia therapy. ( Cha, R; He, C; Liu, Q; Mu, G; Ren, H; Wang, J; Wang, M; Xie, Q; Zhang, Q, 2021)
"Periodontitis is an inflammation characterized by alveolar bone resorption caused by imbalance in bone homeostasis."	5.56	Chloroquine and 3-Methyladenine Attenuates Periodontal Inflammation and Bone Loss in Experimental Periodontitis. ( Chen, B; He, S; Li, L; Luo, B; Yan, F; Zhou, Q, 2020)
"Psoriasis is an unchecked chronic inflammation characterized by thick, erythematous, and scaly plaques on the skin."	5.56	Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A, 2020)
"Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease."	5.56	The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020)
"Galangin was found to reduce the fatty degeneration of liver tissue induced by eating an HFD at both the prevention and treatment levels, and that effect might be related to an enhancement of hepatocyte autophagy."	5.56	Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy. ( Chen, K; Deng, Y; Liao, J; Liu, B; Liu, H; Liu, J; Pu, Y; Xiang, J; Zhang, J; Zhang, X, 2020)
"UNC2025 is a small molecule inhibitor of the Mer tyrosine kinase."	5.48	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. ( Acevedo, G; Branchford, BR; Brass, LF; Brzezinski, C; Davizon-Castillo, P; DeRyckere, D; Di Paola, JA; Frye, SV; Graham, DK; Law, L; Lee-Sherick, AB; Lentz, SR; Minson, K; Neeves, KB; Ng, C; Sather, S; Shelton Earp, H; Stalker, TJ; Wang, X; Wilson, KM; Zhang, W, 2018)
"Renal fibrosis is a common pathological feature of the progression of chronic kidney disease."	5.46	Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017)
"WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α."	5.43	Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. ( Akchurin, O; Boskey, A; Choi, ME; Cunningham-Rundles, S; Doty, SB; Patino, E; Rivella, S; Sureshbabu, A; Zhu, YS, 2016)
"Sinomenine (SIN) is a natural alkaloid extracted from Chinese medicinal plant Sinomenium acutum, and its hydrochloride salt (Sinomenine hydrochloride, SIN-HCl) is widely used to treat rheumatoid arthritis (RA)."	5.42	Sinomenine hydrochloride protects against polymicrobial sepsis via autophagy. ( Chen, G; Gao, M; Jiang, Y; Lang, Y; Liu, M; Tong, Z; Wang, K; Wang, W; Xiao, X; Yao, Y; Zhang, H, 2015)
"Medial vascular calcification is highly prevalent in chronic kidney disease (CKD), and it is a risk factor for mortality."	5.39	Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. ( Adams, MA; Holden, RM; Pang, J; Shobeiri, N, 2013)
" The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance."	5.35	Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008)
"1."	5.34	Strontium fructose 1,6-diphosphate rescues adenine-induced male hypogonadism and upregulates the testicular endothelin-1 system. ( Dai, DZ; Dai, Y; Feng, Y; Ying, HJ; Zhang, Q, 2007)
"Adefovir was administered for six consecutive days starting one day before or four days after DHBV inoculation."	5.31	Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. ( Delmas, J; Gibbs, C; Hantz, O; Jamard, C; Schorr, O; Trépo, C; Zoulim, F, 2002)
"Hyperthyroidism was associated with a 20% increase in adenosine kinase, 30% decrease in membrane 5'-nucleotidase and 15% decrease in adenosine deaminase activities measured in heart homogenates."	5.29	Hyperthyroidism increases adenosine transport and metabolism in the rat heart. ( Seymour, AM; Smolenski, RT; Yacoub, MH, 1995)
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."	4.85	Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
"Colchicine inhibited tubulin polymerization and caspase-1 activation and attenuated kidney inflammation and fibrosis in a mouse model of adenine-induced KI."	4.31	Beneficiary Effects of Colchicine on Inflammation and Fibrosis in a Mouse Model of Kidney Injury. ( Arazi, E; Landau, D; Segev, Y; Shukri, N; Tobar, A, 2023)
"We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet."	4.12	Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022)
" We also investigated its efficacy in unilateral ureteral obstruction (UUO)-treated mice and in adenine-induced CKD rats."	4.12	Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease. ( Du, P; Wang, H; Wang, T; Yang, M; Yin, H, 2022)
"In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice."	4.12	Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022)
" Mouse fibrotic kidney samples were collected from male C57BL/6J mice treated with an adenine-rich diet for 14 days or were subjected to 7 days of unilateral ureteral obstruction (UUO)."	4.02	Consistent alteration of chain length-specific ceramides in human and mouse fibrotic kidneys. ( Beyer, S; Boor, P; Djudjaj, S; Eckes, T; Gauer, S; Koch, A; Patyna, S; Pfeilschifter, J; Schaefer, L; Schwalm, S; Thomas, D; Trautmann, S, 2021)
" The characterizations were analyzed by physicochemical methods, and the renoprotections were processed in adenine-induced chronic kidney diseases (CKD) models of mice."	4.02	Renoprotective effects of enzyme-hydrolyzed polysaccharides from Auricularia polytricha on adenine-induced chronic kidney diseases in mice. ( Cui, W; Jia, L; Li, J; Pang, H; Song, X; Zhang, J, 2021)
"2% adenine diet for 14 weeks developed CKD with elevated plasma levels of TMAO, provision of a non-lethal inhibitor of gut microbial trimethylamine (TMA) production, iodomethylcholine (IMC), significantly reduced multiple markers of renal injury (plasma creatinine, cystatin C, FGF23, and TMAO), reduced histopathologic evidence of fibrosis, and markedly attenuated development of microalbuminuria."	4.02	Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. ( Charugundla, S; Guo, F; Hazen, SL; Jia, X; Kaczor-Urbanowicz, KE; Lusis, AJ; Magyar, C; Miikeda, A; Nicholas, SB; Pellegrini, M; Shih, DM; Wang, Z; Zhang, W; Zhou, Z; Zuckerman, J, 2021)
" We used two animal models of renal fibrosis generated by a unilateral ureteral obstruction (UUO) and an adenine diet (AD) to investigate whether SAMiRNA-AREG inhibited renal fibrosis."	4.02	In vivo silencing of amphiregulin by a novel effective Self-Assembled-Micelle inhibitory RNA ameliorates renal fibrosis via inhibition of EGFR signals. ( Hwang, S; Kim, TR; Ko, Y; Lee, EY; Lee, JH; Park, HO; Park, JH; Son, B; Son, SS; Yun, SI, 2021)
" Importantly, the neuron-protective effect of MDL-28170 on ischemic insult was reversed by cotreatment with either class III-PI3K (phosphatidylinositol 3-kinase) inhibitor 3-methyladenine or lysosomal inhibitor chloroquine (chloroquine), suggesting that CAPN1 activation-mediated impairment of autophagic flux is crucial for cerebral ischemia-induced neuronal damage."	4.02	CAPN1 (Calpain1)-Mediated Impairment of Autophagic Flux Contributes to Cerebral Ischemia-Induced Neuronal Damage. ( Cai, R; Che, X; Fu, X; Liu, Y; Luo, J; Yang, J; Yang, Y; Yao, Y; Yu, X; Zhang, H; Zhou, MS, 2021)
"Uremia was induced by feeding Wistar rats an adenine-enriched diet (0."	3.96	Digital radiography as an alternative method in the evaluation of bone density in uremic rats. ( Carmo, WB; Castro, BBA; Custodio, MR; Jorgetti, V; Oliveira, RSMF; Peters, VM; Sanders-Pinheiro, H, 2020)
"Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively."	3.96	Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. ( Hitomi, H; Kittikulsuth, W; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Osafune, K; Yamazaki, D, 2020)
"To investigate the protective effects of autophagy inhibitor 3-methyladenine (3-MA) in a rat model of ischemic-reperfusion injury (IRI)."	3.96	Protective effects of autophagy inhibitor 3-methyladenine on ischemia-reperfusion-induced retinal injury. ( Wang, X; Wu, Y, 2020)
" Here we investigated long-term effects of PHDI treatment in adenine-induced nephropathy as a model for chronic tubulointerstitial nephritis."	3.91	Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis. ( Beneke, A; Burzlaff, N; Daniel, C; Eckardt, KU; Goppelt-Struebe, M; Herrmann, M; Jantsch, J; Kalucka, J; Katschinski, DM; Klanke, B; Mayer, M; Palsson, R; Schatz, V; Schley, G; Thorsteinsdottir, M; Weidemann, A; Willam, C, 2019)
"The elevated level of the amino acid metabolite homocysteine (Hcy) is known as a risk factor for ischemic stroke."	3.91	Homocysteine enhances neural stem cell autophagy in in vivo and in vitro model of ischemic stroke. ( Cheng, M; Liang, X; Liu, H; Sai, N; Wang, M; Wang, X; Yang, L; Zhang, X, 2019)
" We used a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigate whether TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection."	3.91	Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques. ( Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S, 2019)
"After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects."	3.88	Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018)
" Here, we established a rat model with secondary hyperparathyroidism (SHPT) and bone disease induced by adenine and a high phosphorous diet and analyzed the skeletal characteristics."	3.88	A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet. ( Chen, Q; Liu, BC; Lv, LL; Ni, HF; Ni, LH; Song, KY; Tang, RN; Wang, B; Wang, FM; Wang, LT; Wu, M, 2018)
"Adenine mice exhibited significantly higher mean serum urea, creatinine, and renal expression of the pro-inflammatory markers Interleukin-6 (IL-6), C-X-C motif chemokine 10 (CXCL10), and Interleukin-1β (IL-1β), in addition to prominent renal fibrosis and reduced renal Klotho gene expression compared to the control."	3.88	Fish Oil Supplementation Reduces Inflammation but Does Not Restore Renal Function and Klotho Expression in an Adenine-Induced CKD Model. ( Baia, LC; de Borst, MH; Heilberg, IP; Henao Agudelo, JS; Machado, JR; Navis, GJ; Ormanji, MS; Santos, ARP; Saraiva Câmara, NO, 2018)
"This work aims to explore the amelioration of fucoidan on adenine-induced hyperuricemia and hepatorental damage."	3.88	Production Inhibition and Excretion Promotion of Urate by Fucoidan from ( Li, Y; Liu, H; Luo, P; Zhang, D, 2018)
"We show that simvastatin treatment mediates activation of autophagy in BSMCs, which is correlated with airway inflammation and airway remodelling in mouse models of asthma."	3.85	Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma. ( Cui, R; Ding, T; Gu, W; Guo, X; Han, F; Li, X; Peng, J; Xu, W, 2017)
" Folic acid-induced acute kidney injury increased calvaria FGF23 mRNA and serum FGF23 and parathyroid hormone (PTH) levels at 6 h."	3.83	The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. ( Durlacher, K; Hassan, A; Levi, R; Naveh-Many, T; Silver, J, 2016)
"To study the therapeutic effect of chrysin, a flavonoid with strong antioxidant and anti-inflammatory activities, on adenine-induced chronic kidney diseases (CKD) in rats."	3.83	Therapeutic Effect of Chrysin on Adenine-Induced Chronic Kidney Disease in Rats. ( Adham, SA; Al Za'abi, M; Ali, BH; Nemmar, A; Schupp, N; Yasin, J, 2016)
"A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)."	3.83	Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016)
" Adenine (5, 10, and 50 mg/kg BW/day) was administered orally for 14 days to female BALB/c mice, and then 5% dextran sodium sulfate (DSS) was given to induce colitis."	3.83	Adenine Inhibits TNF-α Signaling in Intestinal Epithelial Cells and Reduces Mucosal Inflammation in a Dextran Sodium Sulfate-Induced Colitis Mouse Model. ( Fukuda, T; Majumder, K; Matsui, T; Mine, Y; Turner, PV; Zhang, H, 2016)
" Here, we studied whether a specific inhibitor of the Nlrp3 inflammasome, CP-456,773, can prevent kidney fibrosis in a murine model of crystal nephropathy induced by diets rich in oxalate or adenine."	3.83	An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. ( Bartok, E; Boor, P; Dhana, E; Evers, BD; Franklin, BS; Hall, JP; Hartmann, G; Hornung, V; Knolle, PA; Kurts, C; Latz, E; Ludwig-Portugall, I; Primiano, MJ, 2016)
"This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy."	3.81	Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015)
" Sodium thiosulfate (STS) due to its multiple properties such as antioxidant and calcium chelation has been reported to prevent vascular calcification in uremic rats, without mentioning its impact on cerebral function."	3.81	Sodium thiosulfate protects brain in rat model of adenine induced vascular calcification. ( Kurian, GA; Sriram, R; Subhash, N, 2015)
"Calcitriol and various analogs are commonly used to suppress secondary hyperparathyroidism in chronic kidney disease but may also exacerbate vascular calcification."	3.80	Role of local versus systemic vitamin D receptors in vascular calcification. ( Lomashvili, KA; O'Neill, WC; Wang, X, 2014)
"In order to evaluate the efficacy, and explore the mechanism of SDG to inhibit the progression of renal fibrosis, study was carried out using the adenine-induced Wister rats as the CRF model, and losartan as postive control drug."	3.80	Chinese herbal medicine Shenqi Detoxification Granule inhibits fibrosis in adenine induced chronic renal failure rats. ( Cai, P; Ma, H; Meng, H; Peng, M; Si, G; Xu, Y; Zhang, X, 2014)
"Our previous studies demonstrated that the topical application of caffeine is a potent inhibitor of UVB-induced carcinogenesis and selectively increases apoptosis in tumors but not in non-tumor areas of the epidermis in mice that are at a high risk for developing skin cancer."	3.80	PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis. ( Bernard, JJ; Li, T; Lou, YR; Lu, YP; Peng, QY, 2014)
"Adenine overload promotes intratubular crystal precipitation and interstitial nephritis."	3.79	NF-κB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy. ( Arias, SC; Barlette, GP; Borges, RL; Camara, NO; de Almeida, DC; Fanelli, C; Fujihara, CK; Machado, FG; Malheiros, DM; Okabe, C; Zatz, R, 2013)
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)."	3.79	Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013)
" The negative impact of inflammation in this CKD model was overcome by the marked anti-inflammatory effects of thalidomide, promoting renal protection."	3.79	Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. ( Blanco, P; Catanozi, S; de Sá Lima, L; Degaspari, S; Dellê, H; Noronha, IL; Santana, AC; Scavone, C; Silva, C; Solez, K, 2013)
"Although one animal had a gradual increase in viremia from 3 years onwards, the other 4 tenofovir-treated animals maintained undetectable viremia with occasional viral blips (≤ 300 RNA copies/ml plasma)."	3.78	Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. ( Abel, K; Canfield, DR; Forthal, DN; Geng, Y; Heneine, W; Jayashankar, K; Johnson, JA; LaBranche, CC; Landucci, G; Lipscomb, J; Montefiori, D; Tarara, RP; Trott, KA; Van Rompay, KK, 2012)
"Since homocysteine (Hcy) is considered a risk factor to cerebral diseases and adenine nucleotides are important molecules to brain normal function, in the present study we investigated the effect of chronic mild hyperhomocysteinemia on ectonucleotidase activities and expression in rat cerebral cortex."	3.78	Mild hyperhomocysteinemia alters extracellular adenine metabolism in rat brain. ( Bogo, MR; Bonan, CD; Casali, EA; Ferreira, AG; Savio, LE; Scherer, EB; Schmitz, F; Tasca, RA; Vuaden, FC; Wyse, AT, 2012)
" The neurotoxicity of pathogenic Machado-Joseph Disease (MJD) glutamine (Q) 78 and 127Q proteins were enhanced by the co-expression of Mo-PrP³(F)⁴in the fly eyes, while the eyes of controls flies and flies expressing Mo-PrP³(F)⁴) alone or together with MJD-Q27 or 20Q proteins did not show any defect."	3.77	Normal prion protein in Drosophila enhances the toxicity of pathogenic polyglutamine proteins and alters susceptibility to oxidative and autophagy signaling modulators. ( Choi, HJ; Choi, JK; Kim, AY; Kim, W; Koh, EK; Koh, YH; Park, N; Park, Y; Seo, J, 2011)
" In particular, we show that systemic injection of 3-methyladenine (3-MA) reduces muscle fibrosis, atrophy, apoptosis and increases muscle regeneration and muscle mass."	3.77	Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. ( Allamand, V; Carmignac, V; Durbeej, M; Elowsson, L; Gawlik, KI; Körner, Z; Matsumura, C; Svensson, M, 2011)
" Uremia-related medial calcification was induced by feeding rats an adenine low-protein diet for 4 weeks."	3.76	Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. ( D'Haese, PC; Dauwe, S; De Broe, ME; De Schutter, T; Neven, E; Persy, V, 2010)
"3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin."	3.75	Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. ( Li, X; Lu, L; Wu, W; Yan, J; Yu, H; Yu, X, 2009)
"Adenine phosphoribosyltransferase deficiency in mice or an excessive oral intake of adenine leads to the accumulation of 2,8-dihydroxyadenine (DHA) in renal tubules and that causes progressive renal dysfunction accompanied by interstitial fibrosis."	3.75	Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. ( Aizawa, R; Hori, M; Ozaki, H; Tamura, M, 2009)
"After adenine dosing, significant hyperphosphatemia, hypocalcemia and secondary hyperparathyroidism (2HPT) were observed during the experimental period of 15 weeks."	3.75	Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. ( Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K, 2009)
" Previous studies have demonstrated an increased susceptibility to genital herpes in mice following repeated applications of nonoxynol-9 (N-9)."	3.75	Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. ( Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS, 2009)
"We reported previously on the emergence and clinical implications of simian immunodeficiency virus (SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune responses in suppressing viremia during tenofovir therapy."	3.74	Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. ( Bischofberger, N; Blackwood, EJ; Heneine, W; Johnson, JA; Lipscomb, J; Marthas, ML; Matthews, TB; North, TW; Pedersen, NC; Singh, RP; Van Rompay, KK, 2007)
"The aim of the present study was to test the hypothesis that inhibition of adenosine deaminase (ADA) enhances the efficiency of signal-transduction of myocardial A1 adenosine receptors in hyperthyroidism."	3.74	Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium. ( Berta, A; Gesztelyi, R; Grenczer, M; Jakab, A; Karsai, D; Kemeny-Beke, A; Pasztor, F; Szentmiklosi, AJ; Vecsernyes, M; Zsuga, J, 2007)
"Oral adefovir dipivoxil (ADV) reduced viral load in transgenic mice expressing hepatitis B virus (HBV)."	3.71	Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. ( Julander, JG; Morrey, JD; Sidwell, RW, 2002)
"It has been reported that 9-ethyladenine (9-EA) is an efficient inhibitor of APRT (adenine phosphoribosyltransferase) and that its administration causes self-injurious behavior (Lesch-Nyhan Syndrome-like symptoms) in HPRT (hypoxanthine-guanine phosphoribosyltransferase)-deficient mice."	3.70	No self-injurious behavior was found in HPRT-deficient mice treated with 9-ethyladenine. ( Edamura, K; Sasai, H, 1998)
" In order to further evaluate the role of adenosine in seizure activity, we monitored adenosine and its major biochemical metabolites inosine, xanthine, and hypoxanthine in the dorsal hippocampus by in vivo microdialysis before and during the induction of generalized seizures."	3.70	Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. ( Aden, U; Berman, RF; Fredholm, BB; O'Connor, WT, 2000)
" Lesch-Nyhan syndrome is a severe neurological disorder, caused by a deficiency in the purine salvage enzyme hypoxanthine phosphoribosyltransferase (HPRT)."	3.69	Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8-dihydroxyadenine lithiasis. ( Melton, DW; Redhead, NJ; Selfridge, J; Wu, CL, 1996)
"The inherited disease Lesch-Nyhan syndrome, which is caused by a deficiency of the enzyme hypoxanthine phosphoribosyltransferase (HPRT), is characterized by behavioural alterations, including self-injurious behaviour and mental retardation."	3.68	Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. ( Melton, DW; Wu, CL, 1993)
"Three hundred four animals were used for the systematic evaluation of the in vivo efficacy of 5-iodo-2'-deoxyuridine (IUDR), cytosire arabinoside, 9-beta-arabinofuranosyladenine, and isoprinosine in the therapy of herpes simplex encephalitis in an adult rat model."	3.65	Evaluation of four antiviral agents in the treatment of herpes simplex encephalitis in a rat model. ( Marks, MI, 1975)
"A hairless mouse-herpes simplex virus skin infection experimental model was used to evaluate the efficacy of the antiviral compounds 9-beta-d-arabinofuranosyladenine (ara-A), 5-iodo-2'-deoxyuridine (IUdR), and 6-azauridine (aza-U)."	3.65	Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds. ( Brady, E; Friedman-Kien, AE; Klein, RJ, 1974)
"A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells."	2.82	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. ( Barrett, DM; Beckwith, KA; Byrd, JC; Cogdill, AP; Cook, DR; Do, P; Fraietta, JA; Gill, S; Hulitt, J; Johnson, AJ; June, CH; Kudchodkar, SB; Lacey, SF; Levine, BL; Long, M; Maddocks, K; Maus, MV; McGettigan, SE; Melenhorst, JJ; Muthusamy, N; Patel, PR; Porter, DL; Ruella, M; Woyach, JA; Xu, J; Zhang, C; Zheng, Z, 2016)
"At the molecular level, Parkinson's disease share common molecular signatures with most neurodegenerative diseases including the accumulation of misfolded proteins in the brain."	2.61	Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. ( Gonzalez, C; Hetz, C; Lopez, N; Martinez, A, 2019)
" Optimal PrEP agents and dosing regimens now need to be identified."	2.48	Considerations regarding antiretroviral chemoprophylaxis in MSM. ( Grulich, AE; Poynten, IM; Zablotska, I, 2012)
" Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum."	2.40	Animal studies of prophylaxis. ( Black, RJ, 1997)
"Approximately 80% of pancreatic cancer patients suffer from cachexia, and one-third die due to cachexia-related complications such as respiratory failure and cardiac arrest."	1.72	Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer. ( Arneson-Wissink, PC; Bamlet, WR; Cho, DS; Dasgupta, A; Doles, JD; Ducharme, AM; Fernandez-Zapico, ME; Hogenson, TL; Krueger, EW; Razidlo, GL; Schmitt, RE; Zhang, L, 2022)
"Renal fibrosis is an inevitable outcome of various manifestations of progressive chronic kidney diseases (CKD)."	1.72	The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice. ( Alolga, RN; Bian, XY; Chen, C; Jiang, H; Li, J; Liu, HL; Liu, SJ; Liu, YF; Shan, JJ; Si, ZL; Tan, NH; Wang, H; Wu, WH; Zhang, ZH; Zhou, W, 2022)
"However, its functions in diabetic nephropathy (DN) have not been determined."	1.62	METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α-klotho. ( Deng, L; Li, M; Xu, G, 2021)
"Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection."	1.62	Activity of Galidesivir in a Hamster Model of SARS-CoV-2. ( Babu, YS; Bielefeldt-Ohmann, H; Bowen, R; Demarest, JF; DeSpirito, M; Hartwig, A; Mathis, A; Taylor, R; Walling, DM, 2021)
"Sepsis is a life-threatening condition which affects multiple organs including the kidney."	1.62	Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice. ( Ahmad, SF; Al-Harbi, NO; Alanazi, WA; Alqahtani, F; Alsanea, S; Attia, SM; Ibrahim, KE; Mahmood, HM; Nadeem, A, 2021)
" Potentially, lower IFN-α and IP-10 levels as well as once-weekly intranasal dosing vs daily subcutaneous or intramuscular dosing with recombinant type I IFNs could explain the lack of pregnancy effects; however, there was an undesired impact on offspring immune function."	1.62	GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys. ( Baker, A; Bray, M; Hillegas, AE; Maier, CC; Phadnis-Moghe, AS; Posobiec, LM; Price, MA; Stanislaus, DJ, 2021)
"Periodontitis is a common chronic disease."	1.62	Syndecan 4 contributes to osteoclast differentiation induced by RANKL through enhancing autophagy. ( Han, Z; Jing, B; Li, J; Lin, Y; Sun, Z; Yan, H; Yan, Y, 2021)
"Psoriasis is the most prevalent inflammatory skin disorders, affecting 1-3% of the worldwide population."	1.62	DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters. ( Cao, S; Chen, L; He, S; Huang, Y; Lin, Z; Liu, Y; Tang, W; Yang, X; Zhu, F; Zuo, J, 2021)
"Phosphate binders are most used to treat hyperphosphatemia and it is significant to develop its alternatives with high specific and low cost in the clinic."	1.62	Adsorptivity of cationic cellulose nanocrystals for phosphate and its application in hyperphosphatemia therapy. ( Cha, R; He, C; Liu, Q; Mu, G; Ren, H; Wang, J; Wang, M; Xie, Q; Zhang, Q, 2021)
"FSTL1 promotes CS-induced COPD by modulating autophagy, therefore targeting FSTL1 and autophagy may shed light on treating cigarette smoke-induced COPD."	1.62	FSTL1 aggravates cigarette smoke-induced airway inflammation and airway remodeling by regulating autophagy. ( Cao, L; Dong, L; Huang, S; Liu, T; Liu, X; Liu, Y; Pan, Y; Wang, J; Wu, J; Xu, J; Zhao, J; Zou, M, 2021)
"Secondary hyperparathyroidism is a complication of chronic renal failure that is associated with cardiovascular disease."	1.62	Parathyroid Hormone Induces Transition of Myofibroblasts in Arteriovenous Fistula and Increases Maturation Failure. ( Chen, CH; Chen, CY; Hsieh, HL; Hsu, SC; Huang, PH; Lin, FY; Liu, CT; Shih, CM; Shiu, YT; Sue, YM, 2021)
"A mouse model of human Familial Adenomatous Polyposis responds favorably to pharmacological inhibition of 5'-methylthioadenosine phosphorylase (MTAP)."	1.62	Transition state analogue of MTAP extends lifespan of APC ( Augenlicht, LH; Basu, I; Feng, M; Firestone, RS; Peregrina, K; Schramm, VL, 2021)
"Cardiorenal syndrome is a major cause of mortality in patients with chronic kidney disease (CKD)."	1.56	The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. ( Abe, T; Akiyama, Y; Asaji, K; Fukuda, S; Ho, HJ; Ito, S; Iwasaki, T; Kanemitsu, Y; Kikuchi, K; Kure, S; Matsuhashi, T; Mishima, E; Nanto-Hara, F; Oikawa, Y; Owada, Y; Saigusa, D; Soga, T; Suzuki, C; Suzuki, T; Tomioka, Y; Tsukimi, T, 2020)
"Periodontitis is an inflammation characterized by alveolar bone resorption caused by imbalance in bone homeostasis."	1.56	Chloroquine and 3-Methyladenine Attenuates Periodontal Inflammation and Bone Loss in Experimental Periodontitis. ( Chen, B; He, S; Li, L; Luo, B; Yan, F; Zhou, Q, 2020)
" This study assessed the in vitro and in vivo functionality of CAR T cells transduced to express the anti-CD19 CAR of liso-cel in combination with ibrutinib or acalabrutinib."	1.56	Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. ( Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA, 2020)
"Psoriasis is an unchecked chronic inflammation characterized by thick, erythematous, and scaly plaques on the skin."	1.56	Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A, 2020)
"Preeclampsia is a devastating hypertensive disorder of pregnancy with unknown mechanism."	1.56	The Inhibition of Protein Kinase C β Contributes to the Pathogenesis of Preeclampsia by Activating Autophagy. ( Cui, Y; Gong, L; Jing, T; Li, X; Lu, H; Ma, D; Tang, Y; Wu, S; Xiao, X; Xu, H; Zhang, J; Zhao, H; Zhou, Q, 2020)
"Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease."	1.56	The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020)
"Ferulic acid (FA) is a phenolic acid endowed with strong antioxidative and cytoprotective activities."	1.56	Ferulic acid protects cardiomyocytes from TNF-α/cycloheximide-induced apoptosis by regulating autophagy. ( Chen, L; Coffie, JW; Fang, L; Fang, Z; Gao, X; Li, C; Ma, L; Song, M; Wang, H; Wang, Q; Wang, S; Yang, W; Zhang, L, 2020)
"Pancreatic cancer is one of the most lethal human cancers."	1.56	Upregulation of METTL14 mediates the elevation of PERP mRNA N ( Feng, Y; Gong, J; Guo, J; Guo, X; He, C; He, R; Jiang, J; Li, M; Li, X; Liu, J; Miao, J; Peng, F; Qin, R; Shi, C; Tian, R; Wang, M; Wei, W; Xie, Y; Xu, S; Xu, X; Yu, S; Zhang, H; Zhao, Y; Zhu, F, 2020)
"Galangin was found to reduce the fatty degeneration of liver tissue induced by eating an HFD at both the prevention and treatment levels, and that effect might be related to an enhancement of hepatocyte autophagy."	1.56	Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy. ( Chen, K; Deng, Y; Liao, J; Liu, B; Liu, H; Liu, J; Pu, Y; Xiang, J; Zhang, J; Zhang, X, 2020)
"Rabies is an important zoonotic disease in Iran."	1.56	Role of autophagy in nerve cell apoptosis in mice infected with street rabies virus. ( Abdoli, A; Bashar, R; Gharibzadeh, S; Heydarabadi, FH; Sayyah, M; Sheikholeslami, F, 2020)
"Adenosine is an important neuromodulator, that has been indicated to be affected by acute and chronic exposure to ethanol."	1.56	Inhibition of ecto-5'-nucleotidase and adenosine deaminase is able to reverse long-term behavioural effects of early ethanol exposure in zebrafish (Danio rerio). ( Da Silva, RS; Lutte, AH; Majolo, JH, 2020)
"Renal fibrosis is one of the main causes of chronic kidney disease."	1.56	Knockdown of CK2α reduces ( Go, G; Lee, SH; Lim, JH; Yoon, YM; Yun, CW, 2020)
"Sepsis is one of the most prevalent diseases in the world."	1.51	Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. ( Al Zoubi, S; Chiazza, F; Coldewey, SM; Collino, M; Collotta, D; Martin, L; O'Riordan, CE; Purvis, GSD; Stiehler, L; Thiemermann, C; Wissuwa, B, 2019)
"Systemic sclerosis is a multisystem inflammatory and vascular lesion leading to extensive tissue fibrosis."	1.51	DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. ( Fan, C; Feng, C; Li, H; Lu, H; Niu, L; Qi, Q; Tang, W; Wu, B; Wu, Y; Zhang, Z; Zuo, J, 2019)
"The role that CXCL12 plays after facial nerve injury remains unknown."	1.51	CXCL12 has therapeutic value in facial nerve injury and promotes Schwann cells autophagy and migration via PI3K-AKT-mTOR signal pathway. ( Gao, D; Li, S; Sun, H; Tang, T; Tang, Y; Zhu, J, 2019)
"Vascular calcification is a common finding in atherosclerosis and in patients with chronic kidney disease."	1.51	AT2 receptor stimulation inhibits phosphate-induced vascular calcification. ( Bai, HY; Higaki, A; Higaki, J; Horiuchi, M; Iwanami, J; Kan-No, H; Kukida, M; Min, LJ; Mogi, M; Okura, T; Shan, BS; Tsukuda, K; Yamauchi, T, 2019)
"To generate a mouse model of type 2 diabetes mellitus (DM), male C57BL/6J mice were fed with high-fat diet and injected with streptozotocin."	1.51	Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes. ( Ham, DS; Jung, HS; Kim, JW; Kim, MJ; Kim, MN; Min, SH; Park, KS; Yoon, KH, 2019)
"Kidney fibrosis is one of the main pathological findings of progressive chronic kidney disease (CKD) although the pathogenesis of renal scar formation remains incompletely explained."	1.51	Chronic kidney disease induced by an adenine rich diet upregulates integrin linked kinase (ILK) and its depletion prevents the disease progression. ( Calleros, L; de Frutos, S; García-Jérez, A; Griera, M; Hatem-Vaquero, M; Luengo, A; O'Valle, F; Rodríguez-Puyol, D; Rodríguez-Puyol, M, 2019)
"Peripheral nerve injury causes neuropathic pain and microglia activation."	1.51	P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents. ( Cui, W; Du, D; Hu, X; Shi, H; Sun, L; Tian, J; Yu, T; Zhang, X, 2019)
"Vascular calcification is highly prevalent in end-stage renal diseases and is predictive of cardiovascular events and mortality."	1.51	Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2. ( An, J; Huang, K; Li, Y; Liang, M; Tong, Q; Wang, C; Xu, W; Zhang, F, 2019)
"Bupropion was used as a probe substrate for hepatic CYP2B function using rat liver microsomes."	1.51	The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats. ( Kucey, AS; RaoPeters, AAE; Tieu, A; Tonial, NC; Urquhart, BL; Velenosi, TJ, 2019)
"Kidney fibrosis was associated with upregulation of 6-keto-PGI2/TXB2 in the rat kidney tissue."	1.51	Comparison of the Effects of Indobufen and Warfarin in a Rat Model of Adenine-Induced Chronic Kidney Disease. ( Gong, J; He, Q; Jin, J; Li, Y; Lou, X; Zhao, L, 2019)
"Accumulated evidence demonstrates that Japanese encephalitis virus (JEV) infection triggers endoplasmic reticulum (ER) stress and neuron apoptosis."	1.51	Japanese Encephalitis Virus Induces Apoptosis and Encephalitis by Activating the PERK Pathway. ( Ding, Z; Guo, Y; Kong, L; Li, S; Ou, Y; Pan, Z; Tang, Y; Wan, J; Wang, Q; Wang, T; Wu, Y; Xin, X; Yang, Z; Yu, Q; Zhang, Y; Zhu, L, 2019)
"Curcumin was found to significantly abate adenine-induced toxic effects such as reduced creatinine clearance, elevated neutrophil gelatinase-associated lipocalin levels and raised urinary N-acetyl-β-D-glucosaminidase activities."	1.48	Curcumin Ameliorates Kidney Function and Oxidative Stress in Experimental Chronic Kidney Disease. ( Al Abri, N; Al Bahlani, S; Al Dhahli, B; Al Kalbani, J; Al Suleimani, Y; Al Za'abi, M; Al-Salam, S; Ali, BH; Ashique, M; Hartmann, C; Manoj, P; Naser, HT; Nemmar, A; Schupp, N; Yasin, J, 2018)
"UNC2025 is a small molecule inhibitor of the Mer tyrosine kinase."	1.48	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. ( Acevedo, G; Branchford, BR; Brass, LF; Brzezinski, C; Davizon-Castillo, P; DeRyckere, D; Di Paola, JA; Frye, SV; Graham, DK; Law, L; Lee-Sherick, AB; Lentz, SR; Minson, K; Neeves, KB; Ng, C; Sather, S; Shelton Earp, H; Stalker, TJ; Wang, X; Wilson, KM; Zhang, W, 2018)
"Renal fibrosis is a common pathogenic response to injury in chronic kidney disease (CKD)."	1.48	RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase. ( Choi, AM; Choi, ME; Chung, KP; Imamura, M; Moon, JS; Muthukumar, T; Nakahira, K; Ryter, SW; Shingarev, R, 2018)
" There was no inducibility difference after chronic dosing with washout."	1.48	Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib. ( Jones, DL; Tuomi, JM; Xenocostas, A, 2018)
"To evaluate and compare the pharmacokinetic and pharmacodynamic properties of 2 investigational Toll-like receptor 7 agonists, TMX-101, and TMX-202 after intravenous and intravesical administration in a rat model."	1.48	Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model. ( Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA, 2018)
"Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease with high mortality rate."	1.48	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation. ( Gu, Y; Huang, B; Li, H; Lu, G; Qi, M; Xia, D; Yang, Y, 2018)
"Chloroform is a common contaminant in the drinking water."	1.48	3-methyadenine attenuates chloroform-induced hepatotoxicity via autophagy activation. ( Chen, C; Li, X; Wang, L, 2018)
"Metformin-treated rats did not develop hyperphosphatemia or hypocalcemia and this prevented the development of vascular calcification and inhibited the progression toward high bone turnover disease."	1.48	Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. ( Brand, K; D'Haese, PC; De Broe, ME; De Maré, A; Gottwald-Hostalek, U; Kamel, S; Lalau, JD; Neven, E; Opdebeeck, B; Verhulst, A; Vervaet, B, 2018)
"In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer."	1.48	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. ( Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA, 2018)
"Rats with adenine-induced chronic renal failure (ACRF) develop severe renal insufficiency and metabolic abnormalities that closely resemble those in patients with uremia."	1.48	Adenine-Induced Chronic Renal Failure in Rats: A Model of Chronic Renocardiac Syndrome with Left Ventricular Diastolic Dysfunction but Preserved Ejection Fraction. ( Guron, CW; Guron, G; Kashioulis, P; Lundgren, J; Nguy, L; Saeed, A; Shubbar, E, 2018)
"Quercetin-treated model rats had reduced serum levels of parathyroid hormone (PTH), inorganic phosphate, increased urine protein-to-creatinine ratio, increased urine antioxidants, serum lactate dehydrogenase (LDH), and interleukin (IL)-8 when compared with the untreated model group and the control group."	1.48	Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease. ( Li, R; Liang, YN; Song, Y; Yang, H, 2018)
"Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges."	1.48	Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. ( Achille, A; Deng, S; Fonseca, R; Jones, SS; Maharaj, K; Pabon-Saldana, M; Pinilla-Ibarz, J; Powers, JJ; Quayle, SN; Sahakian, E; Sotomayor, EM; Villagra, A, 2018)
" Here we report the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor, DS7423 (hereafter DS), in in-vitro and in-vivo studies."	1.46	Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. ( Gao, F; Hirota, Y; Kaul, I; Koul, D; Koyama, K; Nakayama, K; Saito, N; Setoguchi, M; Shiose, Y; Sulman, EP; Wang, S; Wu, S; Yung, WKA; Zheng, S, 2017)
"Spinal cord ischemia was induced in rats by crossclamping the descending aorta just distal to the left subclavian artery for 14 minutes."	1.46	Acquired inhibition of microRNA-124 protects against spinal cord ischemia-reperfusion injury partially through a mitophagy-dependent pathway. ( Gu, T; Jiang, X; Liu, H; Liu, K; Shi, E; Yan, L; Yu, Y, 2017)
"Baicalein was administrated from 7 to 12 week."	1.46	Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy. ( Cao, X; Kuang, L; Lu, Z, 2017)
"Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them an adenine-containing diet for four weeks."	1.46	PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure. ( Kobayashi, M; Takeda, H; Tatemichi, S; Yaguchi, A, 2017)
"Here we show that treatment of chronic lymphocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB transcriptional activity."	1.46	Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor. ( Allan, JN; Arruga, F; Deaglio, S; Furman, RR; Gaudino, F; Liou, HC; Moscvin, M; Ouk, S; Serra, S; Vaisitti, T; Vitale, N; Zakrzewski, JL, 2017)
"Rhein is an anthraquinone compound isolated from the medicinal plant rhubarb and mainly used in the clinical treatment of diabetic nephropathy."	1.46	Rhein reverses Klotho repression via promoter demethylation and protects against kidney and bone injuries in mice with chronic kidney disease. ( Cao, W; Duan, A; Lin, W; Liu, L; Liu, Z; Yin, S; Zhang, Q, 2017)
"Renal fibrosis is a common pathological feature of the progression of chronic kidney disease."	1.46	Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017)
"Autophagy plays an important role in spinal cord ischemia reperfusion (I/R) injury, but its neuroprotective or neurodegenerative role remains controversial."	1.43	Role of autophagy in the bimodal stage after spinal cord ischemia reperfusion injury in rats. ( Bao, NR; Chen, FS; Fang, B; Li, XQ; Ma, H; Pi, XL; Tan, WF; Zhang, Y, 2016)
"In this study, we established a chronic renal failure (CRF) model in rats induced by adenine administration prior to Mg implantation, aiming to predict if CRF patients are suitable for the use of Mg implants."	1.43	Biodegradable Magnesium (Mg) Implantation Does Not Impose Related Metabolic Disorders in Rats with Chronic Renal Failure. ( Li, Y; Liu, W; Qin, L; Wang, J; Xu, J, 2016)
"Rats with adenine-induced chronic renal failure (A-CRF) develop a reduced rate of relaxation of the thoracic aorta."	1.43	Adenine-induced chronic renal failure in rats decreases aortic relaxation rate and alters expression of proteins involved in vascular smooth muscle calcium handling. ( Guron, G; Jernås, M; Lundgren, J; Nguy, L; Nilsson, H; Nookaew, I; Olsson, B; Shubbar, E, 2016)
"Ibrutinib treatment impacts HER2(+) breast cancer cell viability at lower concentrations than the established breast cancer therapeutic lapatinib."	1.43	Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. ( Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J, 2016)
"WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α."	1.43	Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. ( Akchurin, O; Boskey, A; Choi, ME; Cunningham-Rundles, S; Doty, SB; Patino, E; Rivella, S; Sureshbabu, A; Zhu, YS, 2016)
"Pathogenesis of adenine-induced chronic renal failure may involve inflammatory, immunological and/or oxidant mechanisms."	1.42	High-mobility group box-1 protein in adenine-induced chronic renal failure and the influence of gum arabic thereon. ( Al Shukaili, A; Al Za'abi, M; Ali, BH; Nemmar, A, 2015)
"Sinomenine (SIN) is a natural alkaloid extracted from Chinese medicinal plant Sinomenium acutum, and its hydrochloride salt (Sinomenine hydrochloride, SIN-HCl) is widely used to treat rheumatoid arthritis (RA)."	1.42	Sinomenine hydrochloride protects against polymicrobial sepsis via autophagy. ( Chen, G; Gao, M; Jiang, Y; Lang, Y; Liu, M; Tong, Z; Wang, K; Wang, W; Xiao, X; Yao, Y; Zhang, H, 2015)
" The FDA-recommended rabbit vaginal irritation (RVI) model serves as a first line selection tool for vaginal products; however, for decades it has been limited to histopathology scoring, insufficient to select safe anti-HIV microbicides."	1.42	A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation. ( Chandra, N; Doncel, GF; Fichorova, RN; Mendonca, K; Murray, R; Yamamoto, HS, 2015)
"Chrysin did not cause any overt adverse effect on the treated rats."	1.42	Ameliorative effect of chrysin on adenine-induced chronic kidney disease in rats. ( Adham, SA; Al Za'abi, M; Ali, BH; Nemmar, A; Schupp, N; Waly, MI; Yasin, J, 2015)
" Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL."	1.40	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). ( Bojnik, E; Buggy, JJ; Byrd, JC; Chang, BY; Davis, ME; Dubovsky, JA; Efremov, DG; Gobessi, S; Goettl, VM; Harrington, BK; Johnson, AJ; Laurenti, L; MacMurray, J; Ruppert, AS; Smith, LL; Smucker, KA; Stefanovski, MR; Towns, WH; Woyach, JA, 2014)
"Vascular calcification is highly correlated with increased cardiovascular morbidity and mortality."	1.40	Overexpression of c1q/tumor necrosis factor-related protein-3 promotes phosphate-induced vascular smooth muscle cell calcification both in vivo and in vitro. ( Feng, H; Lei, H; Li, H; Li, L; Wang, C; Wang, JY; Wu, D; Wu, LL; Zhou, Y, 2014)
"Malnutrition and inflammation are also closely linked to an increased risk of cardiovascular death in CKD."	1.40	Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. ( Kitazono, T; Masutani, K; Nakano, T; Noguchi, H; Ooboshi, H; Taniguchi, M; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S, 2014)
" A control group (n=34) received no drug, a second group (n=6) received oral tenofovir disoproxil fumarate/emtricitabine 3 days before each virus challenge and a third group (n=6) received the same dosing plus another dose 2 h after virus challenge."	1.40	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. ( Anderson, PL; Bushman, LR; García-Lerma, JG; Glidden, DV; Heneine, W, 2014)
" Significant improvement in survival was observed after treatment with BCX4430 at 4 mg/kg of body weight per day dosed intraperitoneally (i."	1.40	BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. ( Babu, YS; Bantia, S; Julander, JG; Kotian, P; Minning, DM; Morrey, JD; Sheridan, WP; Smee, DF; Taubenheim, BR, 2014)
"After 1 week, rats with chronic renal failure were treated with vehicle, 375 or 750 mg/kg CaMg, or 750 mg/kg sevelamer by daily gavage for 5 weeks."	1.39	Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. ( Behets, GJ; D'Haese, PC; De Schutter, TM; Geryl, H; Gundlach, K; Neven, E; Passlick-Deetjen, J; Peter, ME; Steppan, S, 2013)
"The adenine group was subdivided into a model control group (n = 7), a positive control group (200 mg/kg Jinshuibao capsule (JSB; n = 8), and two IF groups (200 mg/kg, n = 8; 100 mg/kg, n = 8)."	1.39	Nephroprotective effects of Isaria felina in rats with adenine-induced chronic renal failure. ( Bai, X; Ren, L; Yang, X; Zhang, H; Zhang, S, 2013)
"Medial vascular calcification is highly prevalent in chronic kidney disease (CKD), and it is a risk factor for mortality."	1.39	Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. ( Adams, MA; Holden, RM; Pang, J; Shobeiri, N, 2013)
"Adenine treatment in rats has been proposed as an animal model of anemia of CKD with high hepcidin levels that mirrors the condition in human patients."	1.39	A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. ( Babitt, JL; Brown, DE; Cappellini, MD; Chen, S; Hong, CC; Lin, HY; Stepanek, A; Sun, CC; Theurl, I; Vaja, V; Weiss, G, 2013)
" When dosed into the lung the compounds were rapidly metabolized and short-term exposure of the 'antedrug' was sufficient to activate the IFN pathway."	1.38	Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity. ( Aoki, M; Benjamin, AD; Biffen, M; Doyle, I; Edwards, S; Eiho, K; Fraser, NJ; Hawkins, SL; Holness, E; Leishman, AJ; Matsui, H; McInally, T; Murray, CM; Satterthwaite, G; Takaku, H; Tomizawa, H; Wada, H, 2012)
"In the brains of patients with fetal Minamata disease (FMD), which is caused by exposure to methylmercury (MeHg) during development, many neurons are hypoplastic, ectopic, and disoriented, indicating disrupted migration, maturation, and growth."	1.38	Rescue of neuronal migration deficits in a mouse model of fetal Minamata disease by increasing neuronal Ca2+ spike frequency. ( Fahrion, JK; Galas, L; Komuro, H; Komuro, Y; Li, Y; Littner, Y; Ohno, N; Raoult, E; Vaudry, D, 2012)
"Similar to ADPKD, Pkd1 cKO mice developed renal and hepatic cysts."	1.38	CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. ( Bukanov, NO; Galons, H; Ibraghimov-Beskrovnaya, O; Ledbetter, SR; Meijer, L; Moreno, SE; Natoli, TA; Oumata, N; Rogers, KA; Smith, LA, 2012)
"Acetaminophen is a safe antipyretic and analgesic drug within the clinically recommended dosage range, but overdose can cause fatal liver and or kidney damage."	1.38	Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats. ( Arimizu, K; Chuang, VT; Hirata, S; Irie, T; Ishitsuka, Y; Kadowaki, D; Kitamura, K; Maruyama, T; Narita, Y; Otagiri, M; Sumikawa, S; Taguchi, K, 2012)
"These results demonstrate rat bone cancer pain could partially relieved after intrathecal injection of P2Y12 receptor inhibitor MRS2395 through inhibiting the phosphorylation of p38MAPK in spinal dorsal horn."	1.38	[Influence of P2Y12 receptor inhibitor on pain threshold and spinal p38MAPK in rat bone cancer pain model]. ( Huang, B; Lian, QQ; Liu, MJ; Ni, HD; Sun, JL; Yao, M; Zhou, XY; Zhu, YL, 2012)
"Amonafide is a DNA intercalator in clinical development for the treatment of cancer."	1.37	Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer. ( Appella, DH; Chen, Z; Huang, S; Liu, Y; Lou, G; Norton, JT; Wang, C; Witschi, MA; Xu, Q, 2011)
"Here, we show that systemic treatment of insulinoma-bearing mice with PCI-32765 efficiently inhibits Btk, blocks mast cell degranulation, and triggers collapse of tumor vasculature and tumor regression."	1.37	Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. ( Adimoolam, S; Allende, MT; Buggy, JJ; Evan, GI; Kortlever, R; Monclús, HA; Soucek, L; Swigart, LB, 2011)
"Periodontitis was produced by a ligature placed around the cervix of the two lower first molar."	1.36	Increase nitric oxide synthase activity in parotid glands from rats with experimental periodontitis. ( Borda, E; Busch, L; Miozza, V; S-Borda, L, 2010)
"Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA."	1.36	The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. ( Antonioli, L; Awwad, O; Blandizzi, C; Colucci, R; Da Settimo, F; Duranti, E; Fornai, M; Ghisu, N; La Motta, C; Natale, G; Tuccori, M; Virdis, A, 2010)
" The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance."	1.35	Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008)
"Adenine was dissolved with Arabian sol at the proportion of 1:10 and different adenine solutions were prepared at the concentration of 0, 50, 100, 150 and 200 mg/ml."	1.35	[Construction of the male rat model of adenine-induced infertility with kidney-yang deficiency]. ( Cao, YG; Chen, D; Jia, JM; Wang, JH; Zhou, JG, 2008)
"Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels."	1.35	Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009)
"During the first stage of human African trypanosomiasis (HAT), Trypanosoma brucei gambiense is found mainly in the blood, and pentamidine treatment is used."	1.35	Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. ( De Koning, HP; Dogruel, M; Rodgers, J; Sanderson, L; Thomas, SA, 2009)
" Third, oral adenine dosing for induction of hyperphosphataemia and validation as a model using Sev were examined."	1.35	Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. ( Mizukami, K; Okada, M; Terai, K, 2008)
"At week 9, renal failure resolved with improvement in the hyperparathyroid state."	1.35	Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. ( Abedat, S; Beeri, R; Ben-Dov, IZ; Danenberg, HD; Lotan, C; Meir, K; Planer, D; Shuvy, M; Sosna, J, 2008)
"1."	1.34	Strontium fructose 1,6-diphosphate rescues adenine-induced male hypogonadism and upregulates the testicular endothelin-1 system. ( Dai, DZ; Dai, Y; Feng, Y; Ying, HJ; Zhang, Q, 2007)
"All compounds tested reversed the catalepsy induced by haloperidol."	1.33	New adenosine A2A receptor antagonists: actions on Parkinson's disease models. ( Cristalli, G; Morelli, M; Pinna, A; Volpini, R, 2005)
"However, in chronic renal failure (CRF), serum 1,25(OH)(2)D and Pi levels are often abnormal."	1.33	Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. ( Eto, N; Miyata, Y; Ohno, H; Yamashita, T, 2005)
"Adenine-treated rats showed marked elevations of serum phosphorus, PTH and FGF23 levels associated with parathyroid hyperplasia and aortic calcification."	1.33	[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. ( Abe, M; Kobayashi, N; Miyata, S; Nagano, N; Wada, M; Wakita, S, 2005)
"Bronchial asthma is characterized by inflammation of the airways, which is usually accompanied by increased vascular permeability, resulting in plasma exudation."	1.33	Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma. ( Jin, SM; Kim, SR; Lee, KS; Lee, YC; Min, KH; Park, SJ; Puri, KD, 2006)
"Bilateral mechanical hyperalgesia of the paw was induced by administering two injections of acidic saline, 5 d apart, into the gastrocnemius muscle of male Sprague Dawley rats."	1.32	Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections. ( Hoeger-Bement, MK; Sluka, KA, 2003)
" Pharmacokinetic experiments in mice showed that the oral bioavailabilities of PMEA following oral gavage of Bis-PMEA or PMEA (at a dose equivalent to 28 mg of PMEA/kg) were 50."	1.31	Pharmacokinetic and antiretroviral activity in mice of oral [P(1),P(2)-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine. ( Cappellacci, L; Casabianca, A; Celeste, AG; Cerasi, A; Chiarantini, L; Dominici, S; Franchetti, P; Grifantini, M; Magnani, M; Rossi, L; Serafini, S, 2002)
"Adefovir dipivoxil is a prodrug of adefovir designed to enhance its oral bioavailability."	1.31	Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. ( Brown, C; Cullen, JM; Cundy, KC; Eisenberg, EJ; Gibbs, C; Li, DH; Toole, J; Wolfe, J, 2001)
"Adefovir was administered for six consecutive days starting one day before or four days after DHBV inoculation."	1.31	Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. ( Delmas, J; Gibbs, C; Hantz, O; Jamard, C; Schorr, O; Trépo, C; Zoulim, F, 2002)
"Hemorrhage was induced in 10 female Pitman-Moore mini-pigs to maintain mean arterial blood pressure at 55 mmHg for 90 minutes."	1.30	Comparison of Adsol and CPDA-1 blood preservatives during simulated massive resuscitation after hemorrhage in swine. ( Borgia, JF; Buchholz, DH; Miripol, JE; Simpson, JM; Ward, M, 1999)
"Hyperthyroidism was associated with a 20% increase in adenosine kinase, 30% decrease in membrane 5'-nucleotidase and 15% decrease in adenosine deaminase activities measured in heart homogenates."	1.29	Hyperthyroidism increases adenosine transport and metabolism in the rat heart. ( Seymour, AM; Smolenski, RT; Yacoub, MH, 1995)
"To study whether PMEA also affects visna virus infection in sheep, two groups of four lambs each were inoculated intracerebrally with 10(6."	1.29	Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. ( Balzarini, J; De Clercq, E; Georgsson, G; Naesens, L; Pálsson, PA; Thormar, H; Torsteinsdóttir, S, 1995)

Research

Studies (509)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (2.36)	18.7374
1990's	17 (3.34)	18.2507
2000's	74 (14.54)	29.6817
2010's	300 (58.94)	24.3611
2020's	106 (20.83)	2.80

Authors	Studies
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	7
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
Li, M	5
Deng, L	3
Xu, G	2
Pupyshev, AB	1
Tenditnik, MV	1
Ovsyukova, MV	1
Akopyan, AA	1
Dubrovina, NI	1
Tikhonova, MA	1
Gao, Y	4
Luo, C	2
Rui, T	1
Fan, Y	4
Yao, Y	7
Shen, H	3
Gao, C	3
Wang, T	8
Wang, H	12
Chen, X	10
Zhang, J	16
Li, D	3
Xia, C	1
Li, LL	1
Wang, Z	11
Zhang, M	3
Tao, L	1
Kater, AP	1
Slinger, E	1
Cretenet, G	1
Martens, AW	1
Balasubramanian, S	1
Leverson, JD	1
Eldering, E	1
Matsumoto, T	1
Takayanagi, K	1
Katome, T	1
Kojima, M	1
Taguchi, K	2
Kobayashi, T	1
Xu, B	1
Liu, X	10
Gao, S	3
Melekoglu, E	1
Cetinkaya, MA	1
Kepekci-Tekkeli, SE	1
Kul, O	1
Samur, G	1
Yang, Y	9
Ha, S	1
Jeong, S	1
Jang, CW	1
Kim, J	4
Im, DS	1
Chung, HY	2
Chung, KW	1
Fu, J	1
Li, Q	3
Tu, T	1
Lv, X	1
Yin, X	1
Lv, J	1
Song, Z	2
Qu, J	1
Li, J	15
Gu, F	1
Al Za'abi, M	13
Ali, H	2
Ali, BH	14
Dasgupta, A	1
Arneson-Wissink, PC	1
Schmitt, RE	1
Cho, DS	1
Ducharme, AM	1
Hogenson, TL	1
Krueger, EW	1
Bamlet, WR	1
Zhang, L	13
Razidlo, GL	1
Fernandez-Zapico, ME	1
Doles, JD	1
Ghosh, S	1
Mohammed, Z	1
Singh, I	1
Ito, S	5
Manabe, E	2
Dai, Y	2
Ishihara, M	1
Tsujino, T	2
Pulliam, KE	1
Joseph, B	1
Makley, AT	1
Caldwell, CC	1
Lentsch, AB	1
Goodman, MD	1
Pritts, TA	1
Gao, M	3
Zhang, Z	5
Zhang, Y	16
Che, X	2
Cui, X	1
Wang, M	8
Xiong, Y	2
Taylor, R	3
Bowen, R	1
Demarest, JF	1
DeSpirito, M	1
Hartwig, A	1
Bielefeldt-Ohmann, H	1
Walling, DM	1
Mathis, A	2
Babu, YS	4
Zhou, Y	7
Wei, M	1
Tang, F	2
Wu, X	6
Yang, N	1
Shang, Y	2
Liu, Z	11
Wang, W	6
Li, X	13
Tang, S	1
Meng, D	1
Xia, W	1
Wu, Y	8
Zhou, X	2
Du, P	1
Yang, M	4
Yin, H	3
Tölle, M	1
Henkel, C	1
Herrmann, J	1
Daniel, C	2
Babic, M	1
Xia, M	2
Schulz, AM	1
Amann, K	1
van der Giet, M	1
Schuchardt, M	1
Kim, H	2
Nam, BY	1
Park, J	2
Song, S	2
Kim, WK	1
Lee, K	1
Nam, TW	1
Park, JT	1
Yoo, TH	1
Kang, SW	1
Ko, G	1
Han, SH	1
Wollenhaupt, J	1
Frisch, J	1
Harlacher, E	1
Wong, DWL	1
Jin, H	1
Schulte, C	1
Vondenhoff, S	1
Moellmann, J	1
Klinkhammer, BM	3
Baleanu-Curaj, A	1
Liehn, EA	1
Speer, T	1
Kazakov, A	1
Werner, C	1
van der Vorst, EPC	1
Selejan, SR	1
Hohl, M	1
Böhm, M	1
Kramann, R	2
Biessen, EAL	1
Lehrke, M	1
Marx, N	1
Jankowski, J	1
Maack, C	1
Boor, P	4
Prates Roma, L	1
Noels, H	1
Damrath, JG	1
Metzger, CE	2
Allen, MR	3
Wallace, JM	1
Cieminski, K	1
Flis, DJ	1
Dzik, KP	1
Kaczor, JJ	1
Wieckowski, MR	1
Antosiewicz, J	1
Ziolkowski, W	1
Zhou, W	1
Wu, WH	1
Si, ZL	1
Liu, HL	1
Jiang, H	2
Liu, YF	1
Alolga, RN	1
Chen, C	2
Liu, SJ	1
Bian, XY	1
Shan, JJ	1
Tan, NH	1
Zhang, ZH	3
Peng, X	2
Qiao, B	1
Peng, M	3
Deng, N	1
Yu, R	1
Tan, Z	1
Yu, SY	1
Carlaw, T	1
Thomson, T	1
Birkenshaw, A	1
Basha, G	1
Kurek, D	1
Huang, C	1
Kulkarni, J	1
Zhang, LH	1
Ross, CJD	1
Landau, D	2
Shukri, N	1
Arazi, E	1
Tobar, A	1
Segev, Y	2
Huang, X	7
Gao, L	4
Deng, R	1
Peng, Y	1
Wu, S	4
Lu, J	2
Nanto-Hara, F	1
Kanemitsu, Y	2
Fukuda, S	2
Kikuchi, K	2
Asaji, K	2
Saigusa, D	1
Iwasaki, T	1
Ho, HJ	1
Mishima, E	2
Suzuki, T	3
Suzuki, C	2
Tsukimi, T	1
Matsuhashi, T	1
Oikawa, Y	1
Akiyama, Y	2
Kure, S	1
Owada, Y	1
Tomioka, Y	2
Soga, T	2
Abe, T	2
Castro, BBA	2
Carmo, WB	1
Oliveira, RSMF	1
Peters, VM	1
Jorgetti, V	2
Custodio, MR	2
Sanders-Pinheiro, H	2
Zhou, R	1
Zhu, F	3
Chen, Y	6
Zhu, C	1
Dai, B	1
Qian, X	1
Wang, K	5
Hu, W	2
Chen, F	1
O'Riordan, CE	2
Purvis, GSD	2
Collotta, D	2
Chiazza, F	1
Wissuwa, B	2
Al Zoubi, S	1
Stiehler, L	1
Martin, L	1
Coldewey, SM	2
Collino, M	2
Thiemermann, C	3
Yang, X	10
Cao, Z	2
Wu, P	2
Li, Z	9
Moore, PC	1
Qi, JY	1
Thamsen, M	1
Ghosh, R	1
Peng, J	2
Gliedt, MJ	1
Meza-Acevedo, R	1
Warren, RE	1
Hiniker, A	1
Kim, GE	1
Maly, DJ	1
Backes, BJ	1
Papa, FR	1
Oakes, SA	1
He, S	3
Zhou, Q	5
Luo, B	2
Chen, B	1
Li, L	13
Yan, F	1
Jing, F	1
Long, T	1
He, W	3
Qin, G	1
Zhang, D	5
Chen, L	8
Zhou, J	2
Song, CQ	1
Jiang, T	2
Richter, M	1
Rhym, LH	1
Koblan, LW	3
Zafra, MP	1
Schatoff, EM	1
Doman, JL	1
Cao, Y	1
Dow, LE	1
Zhu, LJ	1
Anderson, DG	1
Liu, DR	3
Xue, W	1
Zhao, J	5
Han, M	1
Zhou, L	3
Liang, P	1
Wang, Y	13
Feng, S	2
Lu, H	3
Yuan, X	2
Han, K	1
Liu, S	3
Cheng, J	2
Wu, L	1
Pei, Y	1
Zhu, Y	9
Jiang, M	1
Wang, C	9
Cui, W	3
Wu, B	1
Qi, Q	1
Li, H	9
Fan, C	1
Feng, C	1
Zuo, J	2
Niu, L	1
Tang, W	2
Yamazaki, D	1
Konishi, Y	1
Morikawa, T	1
Kobara, H	1
Masaki, T	2
Hitomi, H	1
Osafune, K	1
Nakano, D	2
Kittikulsuth, W	2
Nishiyama, A	2
Qin, JS	1
Johnstone, TG	1
Baturevych, A	1
Hause, RJ	1
Ragan, SP	1
Clouser, CR	1
Jones, JC	1
Ponce, R	1
Krejsa, CM	1
Salmon, RA	1
Ports, MO	1
Wang, X	24
Nadeem, A	2
Ahmad, SF	2
Al-Harbi, NO	2
El-Sherbeeny, AM	1
Alasmari, AF	1
Alanazi, WA	2
Alasmari, F	1
Ibrahim, KE	2
Al-Harbi, MM	1
Bakheet, SA	1
Attia, SM	2
An, N	1
Zhong, C	1
Guan, M	1
Jiang, Y	3
Zhang, H	12
Wang, L	14
Ruan, Y	3
Liu, N	5
Shang, H	1
Xing, Y	2
Törmänen, S	2
Lakkisto, P	2
Eräranta, A	2
Kööbi, P	1
Tikkanen, I	2
Niemelä, O	2
Mustonen, J	2
Pörsti, I	2
Mikami, D	1
Kobayashi, M	2
Uwada, J	1
Yazawa, T	1
Kamiyama, K	1
Nishimori, K	1
Nishikawa, Y	1
Nishikawa, S	1
Yokoi, S	1
Kimura, H	1
Kimura, I	1
Taniguchi, T	1
Iwano, M	1
Djudjaj, S	2
Kunter, U	2
Palsson, R	2
Edvardsson, VO	1
Wiech, T	1
Thorsteinsdottir, M	2
Hardarson, S	1
Foresto-Neto, O	1
Mulay, SR	1
Moeller, MJ	1
Jahnen-Dechent, W	1
Floege, J	2
Anders, HJ	1
Al Suleimani, Y	4
Manoj, P	5
Ribeiro, DA	1
Nemmar, A	11
Kang, Y	1
Li, Y	20
Wen, H	1
Zhu, J	6
Zheng, J	2
Feng, Z	1
Makhloufi, C	1
Nicolas, F	1
McKay, N	1
Fernandez, S	1
Hache, G	1
Garrigue, P	1
Brunet, P	1
Guillet, B	1
Burtey, S	1
Poitevin, S	1
Halim, AA	1
Alsayed, B	1
Embarak, S	1
Yaseen, T	1
Dabbous, S	1
Fontaine, O	1
Dueluzeau, R	1
Raibaud, P	1
Chabanet, C	1
Popoff, MR	1
Badoual, J	1
Gabilan, JC	1
Andremont, A	1
Gómez, L	1
Andrés, S	1
Sánchez, J	1
Alonso, JM	1
Rey, J	1
López, F	1
Jiménez, A	1
Yan, Z	1
Zhao, Y	5
Wang, J	14
Huang, L	3
Hu, K	1
Liu, H	10
Guo, Z	2
Song, Y	3
Huang, H	5
Yang, R	1
Owen, TW	1
Al-Kaysi, RO	1
Bardeen, CJ	1
Cheng, Q	1
Cheng, T	1
Wang, B	8
Zhang, Q	9
Ochiai, T	1
Ishiguro, H	2
Nakano, R	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Pilot 12 Month, Randomized, Controlled Trial of Curcumin in Kidney Transplant Recipients[NCT03935958]		20 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-04-11	Terminated (stopped due to Insufficient accrual)
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749]	Phase 1/Phase 2	71 participants (Actual)	Interventional	2010-12-31	Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]	Phase 1/Phase 2	133 participants (Actual)	Interventional	2010-05-31	Completed
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287]		14 participants (Actual)	Interventional	2015-11-30	Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]	Phase 4	10 participants (Actual)	Interventional	2018-01-08	Completed
Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493]	Phase 3	33 participants (Actual)	Interventional	2014-11-07	Completed
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392]	Phase 3	24 participants (Anticipated)	Interventional	2021-09-14	Recruiting
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)[NCT01747486]	Phase 2	42 participants (Actual)	Interventional	2013-01-02	Completed
Efficacy and Safety of Transcranial Pulse Stimulation (TPS) in Older Adults With Mild Neurocognitive Disorder - an Open-label Self-controlled Trial[NCT05331560]		20 participants (Anticipated)	Interventional	2020-01-20	Recruiting
Efficacy of a 24-week Long Term Transcranial Pulse Stimulation (TPS) on Cognition and Brain Structure in Older Adults With Mild Neurocognitive Disorder (NCD)[NCT05602467]		22 participants (Anticipated)	Interventional	2022-11-25	Recruiting
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858]		1,765 participants (Actual)	Observational	2011-03-22	Completed
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]	Phase 3	22 participants (Actual)	Interventional	2019-12-09	Active, not recruiting
Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria.[NCT03868722]	Phase 2/Phase 3	212 participants (Anticipated)	Interventional	2019-10-11	Recruiting
Impact of Vitamin D Enteral Supplementation on Hepcidin Serum Levels and Transfusion Requirements in Surgical and Critically Ill Patients[NCT03001687]		40 participants (Anticipated)	Interventional	2017-01-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

Number of Participants With Treatment Emergent Adverse Events (AEs)

Intervention	Participants (Count of Participants)
Ibrutinib Plus Rituximab	0

Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure

Percentage of Participants Achieving Response

Intervention	participants (Number)
Group 1	27
Group 2	20
Group 3	24

The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months

Progression Free Survival (PFS) at 12 Months

Intervention	percentage of participants (Number)
Group 1	92.6
Group 2	80.0
Group 3	70.8

"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months

Safety During Dose-Limiting Toxicity (DLT) Observation Period

Intervention	percentage of event free participants (Mean)
Group 1	88.7
Group 2	85.0
Group 3	75.0

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2

Food Effect Cohort Assessments

Intervention	participants who experienced DLT (Number)
Group 1	0
Group 2	0

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Number of Participants With Treatment Emergent Adverse Events (AEs)

Intervention	(Number)
Food Effect Cohort	1.65

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

Percentage of Participants Achieving Response

Intervention	Participants (Number)
PCI-32765	116
Food Effect	11

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

Progression Free Survival Rate at 24 Months

Intervention	Percentage of Participants (Number)
Treatment Naive	71
Relapsed/ Refractory	75.3
Food Effect	56.3

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Intervention	Percentage of Participants (Number)
Treatment Naive	96.3
Relapsed/ Refractory	73.6
Food- Effect	NA

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Intervention	ng*h/mL (Geometric Mean)
TDF With a Boosted PI	3466
TAF With a Boosted PI	743
TAF With a Boosted PI and LDV/SOF	868

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Intervention	fmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI	36014
TAF With a Boosted PI	6735
TAF With a Boosted PI and LDV/SOF	6100

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Intervention	fmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI	83.0
TAF With a Boosted PI	926
TAF With a Boosted PI and LDV/SOF	1129

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Intervention	mL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI	86.7
TAF With a Boosted PI	91.0
TAF With a Boosted PI and LDV/SOF	88.1

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Intervention	mg/g (Geometric Mean)
TDF With a Boosted PI	134
TAF With a Boosted PI	118
TAF With a Boosted PI and LDV/SOF	97.3

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Intervention	ug/g (Geometric Mean)
	β2M:Cr ratio	RBP:Cr ratio
TAF With a Boosted PI	224	242
TAF With a Boosted PI and LDV/SOF	178	146
TDF With a Boosted PI	419	436

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
Heat Shock Protein 70 (HSP70) Induction: Chaperonotherapy for Neuroprotection after Brain Injury. Cells, 2020, 09-02, Volume: 9, Issue:9 Topics: Adenine; Animals; Benzoquinones; Brain; Brain Injuries, Traumatic; Cell Death; Disease Models, Anima	2020
Adenine-induced chronic kidney disease in rats. Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:1 Topics: Adenine; Animals; Bone Diseases; Cardiovascular Diseases; Disease Models, Animal; Disease Progressio	2018
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. Biology of the cell, 2019, Volume: 111, Issue:6 Topics: Adenine; Adrenergic alpha-2 Receptor Agonists; Animals; Disease Models, Animal; Endoplasmic Reticulu	2019
Ibrutinib and indolent B-cell lymphomas. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top	2014
Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antiviral chemistry & chemotherapy, 2008, Volume: 19, Issue:3 Topics: Adenine; Animals; Antiviral Agents; Benzamides; Cidofovir; Cytosine; Disease Models, Animal; Drug Di	2008
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV medicine, 2009, Volume: 10, Issue:7 Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly	2009
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert opinion on investigational drugs, 2009, Volume: 18, Issue:11 Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials, Phase I	2009
HIV prevention by oral preexposure prophylaxis. Cold Spring Harbor perspectives in medicine, 2012, Volume: 2, Issue:3 Topics: Adenine; Administration, Oral; Animals; Anti-Retroviral Agents; Disease Models, Animal; Dose-Respons	2012
Considerations regarding antiretroviral chemoprophylaxis in MSM. Current opinion in HIV and AIDS, 2012, Volume: 7, Issue:6 Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic;	2012
Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert review of anti-infective therapy, 2003, Volume: 1, Issue:1 Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA Virus Infection	2003
Animal studies of prophylaxis. The American journal of medicine, 1997, May-19, Volume: 102, Issue:5B Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Administration Schedule; Interferon-	1997
Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice. Advances in experimental medicine and biology, 2001, Volume: 487 Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Disease Models, Animal; Humans; Lewy Bo	2001

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, Oct-10, Volume: 122, Issue:15 Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur	2013
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7 Topics: Adenine; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Marrow; Cell Communication; C	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy	2016

adenine and Disease Models, Animal

Research Excerpts

Research

Studies (509)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Number of Participants With Treatment Emergent Adverse Events (AEs)

Percentage of Participants Achieving Response

Progression Free Survival (PFS) at 12 Months

Safety During Dose-Limiting Toxicity (DLT) Observation Period

Food Effect Cohort Assessments

Number of Participants With Treatment Emergent Adverse Events (AEs)

Percentage of Participants Achieving Response

Progression Free Survival Rate at 24 Months

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Reviews

Trials

Other Studies